Biotech · Public company · San Diego, CA, US
Oncolytics Biotech Inc
Ticker ONCY · SEC CIK 0001129928
Track this companyFree. Adds Oncolytics Biotech Inc to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline6
- AvelumabPhase 2 · Breast Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Ras-mutated Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRIPhase 2 · Ras-mutated Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Breast Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- PelareorepPhase 2 · Breast Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- PelareorepPhase 2 · Ras-mutated Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerPHASE2 · RECRUITING · started Apr 30, 2026ClinicalTrials.gov NCT07446322 · fetched Nov 12, 2026
- INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 13, 2020ClinicalTrials.gov NCT04445844 · fetched Nov 12, 2026
- A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 10, 2020ClinicalTrials.gov NCT04215146 · fetched Nov 12, 2026
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaPHASE1 · COMPLETED · started Oct 24, 2018ClinicalTrials.gov NCT03605719 · fetched Nov 12, 2026
- Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Aug 21, 2015ClinicalTrials.gov NCT02514382 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 24, 2026 · fetched Nov 12, 2026